Wintrust Investments LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 3.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,821 shares of the company’s stock after selling 1,418 shares during the quarter. Wintrust Investments LLC’s holdings in Johnson & Johnson were worth $5,736,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Bluesphere Advisors LLC boosted its stake in shares of Johnson & Johnson by 2.3% during the first quarter. Bluesphere Advisors LLC now owns 2,593 shares of the company’s stock valued at $426,000 after acquiring an additional 59 shares during the last quarter. BFT Financial Group LLC lifted its stake in shares of Johnson & Johnson by 1.2% during the 2nd quarter. BFT Financial Group LLC now owns 5,170 shares of the company’s stock worth $852,000 after purchasing an additional 59 shares during the period. Davis Rea LTD. boosted its holdings in shares of Johnson & Johnson by 2.3% during the second quarter. Davis Rea LTD. now owns 2,666 shares of the company’s stock worth $439,000 after purchasing an additional 60 shares during the last quarter. White Lighthouse Investment Management Inc. grew its position in shares of Johnson & Johnson by 0.7% in the second quarter. White Lighthouse Investment Management Inc. now owns 8,691 shares of the company’s stock valued at $1,432,000 after purchasing an additional 60 shares during the period. Finally, Dumont & Blake Investment Advisors LLC increased its stake in Johnson & Johnson by 0.3% in the second quarter. Dumont & Blake Investment Advisors LLC now owns 19,337 shares of the company’s stock valued at $3,186,000 after purchasing an additional 61 shares during the last quarter. Institutional investors and hedge funds own 67.29% of the company’s stock.
Several analysts have commented on JNJ shares. SVB Leerink restated a “buy” rating on shares of Johnson & Johnson in a report on Thursday, July 29th. Morgan Stanley downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 target price for the company. in a report on Tuesday, September 7th. Finally, Credit Suisse Group set a $193.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday, June 7th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $190.38.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share for the quarter, topping analysts’ consensus estimates of $2.29 by $0.19. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The firm had revenue of $23.31 billion during the quarter, compared to analysts’ expectations of $22.54 billion. During the same period in the prior year, the company earned $1.67 EPS. The firm’s revenue was up 27.1% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 9.65 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Tuesday, August 24th were given a $1.06 dividend. This represents a $4.24 annualized dividend and a dividend yield of 2.57%. The ex-dividend date was Monday, August 23rd. Johnson & Johnson’s payout ratio is 52.80%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Recommended Story: How do investors use RSI to grade stocks?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.